Hemispherx hopes new 'PDUFA V' measure will save Ampligen
This article was originally published in Scrip
Executive Summary
With the fate of Hemispherx Biopharma's chronic fatigue syndrome (CFS) therapy Ampligen once again in the hands of the US FDA, the Philadelphia biotech made no bones about warning investors on 1 August that there were no assurances the data in the company's response would provide adequate evidence of efficacy.